GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hoth Therapeutics Inc (NAS:HOTH) » Definitions » Interest Coverage

Hoth Therapeutics (Hoth Therapeutics) Interest Coverage : N/A (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Hoth Therapeutics Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Hoth Therapeutics's Operating Income for the three months ended in Dec. 2023 was $-1.70 Mil. Hoth Therapeutics's Interest Expense for the three months ended in Dec. 2023 was $0.00 Mil. GuruFocus does not calculate 's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Hoth Therapeutics Inc has enough cash to cover all of its debt. Its financial situation is stable.

The historical rank and industry rank for Hoth Therapeutics's Interest Coverage or its related term are showing as below:


HOTH's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 142.97
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Hoth Therapeutics Interest Coverage Historical Data

The historical data trend for Hoth Therapeutics's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Hoth Therapeutics Interest Coverage Chart

Hoth Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Interest Coverage
Get a 7-Day Free Trial No Debt No Debt No Debt No Debt N/A

Hoth Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only No Debt No Debt No Debt No Debt N/A

Competitive Comparison of Hoth Therapeutics's Interest Coverage

For the Biotechnology subindustry, Hoth Therapeutics's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hoth Therapeutics's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hoth Therapeutics's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Hoth Therapeutics's Interest Coverage falls into.



Hoth Therapeutics Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Hoth Therapeutics's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, Hoth Therapeutics's Interest Expense was $0.00 Mil. Its Operating Income was $-7.69 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.03 Mil.

GuruFocus does not calculate Hoth Therapeutics's interest coverage with the available data.

Hoth Therapeutics's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Here, for the three months ended in Dec. 2023, Hoth Therapeutics's Interest Expense was $0.00 Mil. Its Operating Income was $-1.70 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.03 Mil.

GuruFocus does not calculate Hoth Therapeutics's interest coverage with the available data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Hoth Therapeutics  (NAS:HOTH) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Hoth Therapeutics Interest Coverage Related Terms

Thank you for viewing the detailed overview of Hoth Therapeutics's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Hoth Therapeutics (Hoth Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
1 Rockefeller Plaza, Suite 1039, New York, NY, USA, 10020
Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.
Executives
Jeff Pavell director 1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Robb Knie director, officer: CEO and President C/O INVENTERGY GLOBAL, INC., 900 EAST HAMILTON AVENUE SUITE 180, CAMPBELL CA 95008
Stefanie Johns officer: Chief Scientific Officer 1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Anthony Hayes director 1796 SHADY LANE, COLUMBIA SC 29206
Wayne Linsley director 1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Graig Springer director 1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Spherix Inc 10 percent owner 725 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10022
Vadim Mats director 285 GRAND AVENUE, ENGLEWOOD NJ 07631
Rice Kenneth L Jr director C/O 85 MAIN STREET, HOPKINTON MA 01748
David Sarnoff director 1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
David S. Briones officer: Chief Financial Officer C/O PETRO RIVER OIL COMPANY, 1980 POST OAK BLVD., SUITE 2020, HOUSTON TX 77056
Matthew D. Eitner 10 percent owner 44 BRAMS HILL DRIVE, MAHWAH NJ 07430
Kevin Jess Poor 10 percent owner 750 BEULAHS LANE, IDAHO FALLS ID 83401
James P. Ahern 10 percent owner 20 WEST 64TH STREET, APT 18RS, NEW YORK NY 10023